Amsacrine_is_safe_and_effective_therapy_for_patients_with_myocardial_dysfunction_and_acute_leukemia._The_role_of_amsacrine_in_inducing_remission_in_patients_with_cardiac_disease_and_acute_leukemia_was_evaluated._There_were_17_patients_with_acute_myelogenous_leukemia_(AML),_six_with_acute_lymphocytic_leukemia_(ALL),_and_one_with_biphenotypic_leukemia._In_this_series_of_24_patients_whose_disease_had_relapsed_and_who_had_reduced_left_ventricular_ejection_fraction,_nine_had_a_complete_remission,_seven_with_AML_and_two_with_ALL._In_addition,_four_of_six_with_newly_diagnosed_acute_leukemia_and_reduced_left_ventricular_ejection_fraction_also_responded._Among_nine_patients_who_underwent_endomyocardial_biopsy,_none_had_morphologic_changes_of_sufficient_degree_to_account_for_drug-induced_heart_failure._Patients_with_preexisting_arrhythmias_received_amsacrine_without_incident_if_their_serum_potassium_level_was_higher_than_4.0_mEq/l_at_the_time_of_drug_administration._Amsacrine_is_safe_and_effective_therapy_for_patients_with_acute_leukemia_and_cardiac_disease.